TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17319791
Drug: Different antitumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different antitumor drugs (P0)
Study: 9095608
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl and bupivacaine (group I)
Study: 8455424
Drug: No prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No prednisolone pretreatment followed by interferon therapy
Study: 8455424
Drug: Clinical relapse
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical relapse after therapy
Study: 3094355
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 or 40 mg 3 times daily)
Study: 12877448
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 microg used as needed (FP200PRN)
Study: 1929293
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 g, single dose)
Study: 1929293
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg, every 8 h for a total of four doses)
Study: 31401841
Drug: Zumba intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zumba intervention (twice-weekly group classes)
Study: 31112475
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (n = 211)
Study: 26017129
Drug: Multifaceted quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted quality improvement intervention with a daily checklist, definition of daily care goals during multidisciplinary daily rounds, and clinician prompts.
Study: 21506633
Drug: Multimodal behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal behavior treatment (MBT) with hand massage
Study: 21506633
Drug: Multimodal behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal behavior treatment (MBT) without hand massage
Study: 20799476
Drug: IVN201 (functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVN201 (functional fusion peptide) administered via intralymphatic immunotherapy (ILIT)
Study: 22155903
Drug: Carraguard gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carraguard gel
Study: 12043953
Drug: Extended-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release glipizide GITS (Glucotrol XL) 20 mg once daily
Study: 7737631
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide (25-micrograms bolus)
Study: 7737631
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide (infusion of 50-micrograms/hr)
Study: 1478163
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg
Study: 19690618
Drug: Chlorproguanil-dapsone-artesunate (CDA)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chlorproguanil-dapsone-artesunate (CDA) 2/2.5/4 mg/kg once daily for three days (N = 914)
Study: 24359312
Drug: Intradermal locator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal locator device
Study: 16154851
Drug: Erythropoietin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin at a dose of 500 U/kg/week s.c.
Study: 10357495
Drug: Immediate zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate zidovudine (AZT) treatment
Study: 10357495
Drug: Deferred zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred zidovudine (AZT) treatment
Study: 10357495
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of didanosine (ddI)
Study: 8963481
Drug: Coated levomepromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated levomepromazine tablets
Study: 8963481
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (reference)
Study: 1903663
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy neutron treatment
Study: 1903663
Drug: Conventional megavoltage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional megavoltage x ray treatment (photon treatment)
Study: 28298041
Drug: IV ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibuprofen, scheduled oral acetaminophen, and rescue opioids
Study: 28298041
Drug: IV placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo, scheduled oral acetaminophen, and rescue opioids
Study: 29617523
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg twice daily
Study: 26821227
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day for 2 days)
Study: 26821227
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (840 mg/day of EPA + DHA for 3 weeks) with Dexamethasone
Study: 21789658
Drug: Self‐administered questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered questionnaires
Study: 26985729
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) alone for 15 sessions
Study: 26985729
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) followed by Cognitive-Behavioral Therapy (CBT) integrated with MI (4 MI sessions + 11 CBT sessions)
Study: 20473737
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine therapy (Kunbao Pill and Modified Xiaoyao Pill)
Study: 20473737
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Chinese medicine therapy + psychological intervention)
Study: 15703770
Drug: IC-PGE1 +
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IC-PGE1 + 50 mg sildenafil
Study: 19157723
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy
Study: 23722581
Drug: Intradermal sutures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal sutures
Study: 30087427
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose PORT (>66.60 cGy)
Study: 30087427
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high dose PORT (>70.20 cGy)
Study: 22745114
Drug: D5W-LA group
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W-LA group (6 mL of D5W followed by 6 mL of lidocaine 1.5% with epinephrine 1:200,000)
Study: 22745114
Drug: LA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA group (6 mL of lidocaine 1.5% with epinephrine 1:200,000 alone)
Study: 2656736
Drug: Cabergoline 0.2-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.2-1 mg once weekly
Study: 2656736
Drug: Cabergoline 0.2-0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.2-0.5 mg twice weekly
Study: 25727860
Drug: Sildenafil 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20, 40 or 80 mg three times daily
Study: 18579168
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.03 g/kg/day)
Study: 8694085
Drug: Rimexolone 1%
Normalized name: RIMEXOLONE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimexolone 1% ophthalmic suspension
Study: 10686218
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone alone (T; n = 11)
Study: 8374686
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy administered 3 times a week with a total weekly dose of 0.5 IU/kg
Study: 8374686
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy administered 6 times a week with a total weekly dose of 0.5 IU/kg
Study: 3529360
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of cimetidine treatment followed by 3 weeks of placebo (C1 + P)
Study: 28328086
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment condition (EXP; N = 11)
Study: 28328086
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control condition (TAU; N = 10)
Study: 26439386
Drug: OFD +
Normalized name: OFDZ
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFD + placebo gel (group 1)
Study: 26439386
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg RSV gel + PRF + HA with OFD (group 3)
Study: 25089930
Drug: Sequential fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential fluoxetine
Study: 15793249
Drug: Pramlintide (30-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (30-45 microg) with usual insulin bolus-to-carbohydrate ratio
Study: 10630070
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mesoglycan (1 or 2 vials/day)
Study: 2127834
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg twice daily for 28 days
Study: 7194395
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 150 ml/kg per day
Study: 27810317
Drug: XG-102 900
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: XG-102 900 μg
Study: 27810317
Drug: XG-102 90
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: XG-102 90 μg
Study: 23695545
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (omeprazole 20 mg bid + amoxicillin 1 g bid for 5 days, followed by omeprazole 20 mg bid + tinidazole 500 mg bid + clarithromycin 500 mg bid for an additional 5 days)
Study: 21292420
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) therapy for an average of 6.6 years
Study: 21292420
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonusers of CEE therapy)
Study: 11379675
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ropivacaine
Study: 11379675
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ropivacaine plus 75 microg clonidine
Study: 11379675
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ropivacaine plus 15 microg clonidine
Study: 11379675
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ropivacaine plus 45 microg clonidine
Study: 8351757
Drug: Maintenance Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year
Study: 8351757
Drug: Maintenance Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year and 6 intradermal inoculations
Study: 8351757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intradermal inoculations)
Study: 10720032
Drug: Vehicle infusion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle infusion
Study: 26119203
Drug: Percutaneous interspinous
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous interspinous process spacer (IPS) treatment
Study: 15481651
Drug: antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: antidepressants
Study: 11747248
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of inhaled salbutamol (Albuterol) from the original Glaxo product
Study: 11747248
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of inhaled salbutamol (Albuterol) from generic product 1
Study: 11747248
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg of inhaled salbutamol (Albuterol) from generic product 2
Study: 20645509
Drug: Isobaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric 0.5% bupivacaine (3 ml)
Study: 20645509
Drug: Hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 0.5% bupivacaine (3 ml)
Study: 30897585
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (20 min before, during, and 20 min after endotracheal suctioning)
Study: 27247511
Drug: Saline (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (normal saline infusion)
Study: 26825757
Drug: modified WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified WHO ORS with PHGG 15 g/L
Study: 16943652
Drug: Hypothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia therapy for 24 hours
Study: 14578238
Drug: DOIT (Diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOIT (Diabetes Outpatient Intensive Treatment program)
Study: 10343151
Drug: tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (200 mg)
Study: 1929509
Drug: Ibuprofen 5
Normalized name: ibuprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 5 mg/kg
Study: 7707120
Drug: IFN/5‐FU (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN/5‐FU (9 MIU interferon alfa-2a subcutaneously three times per week, 5‐FU 750 mg/m2/d by continuous intravenous infusion on days 1 to 5, then weekly i.v. bolus)
Study: 7707120
Drug: LV/5‐FU (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV/5‐FU (200 mg/m2/d leucovorin by i.v. infusion plus 5‐FU 370 mg/m2/d by i.v. bolus on days 1 to 5, repeated every 4 weeks)
Study: 2533034
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection therapy
Study: 30928279
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) treatment for 1 week
Study: 28472101
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) treatment for 1 week
Study: 1982764
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) with piroxicam (40 mg)
Study: 30650232
Drug: Overall Compliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall Compliance in TAIL treatment
Study: 30650232
Drug: Specific Compliance
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Compliance in TAIL treatment
Study: 25039889
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg) added to valsartan (80 mg)
Study: 25039889
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg) alone
Study: 16275826
Drug: Surrogate consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surrogate consent for randomized clinical trials of new medications
Study: 14605518
Drug: Standard pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacologic therapy
Study: 8523341
Drug: Deflazacort 24
Normalized name: Deflazacort 24 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 24 mg/day
Study: 28138865
Drug: Sensorial training
Normalized name: SENSORY ORGANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorial training of the posterior thigh in addition to neurodevelopmental treatment
Study: 28138865
Drug: Neurodevelopmental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental treatment only (control group)
Study: 19628934
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment in the UK‐TIA Trial
Study: 15529649
Drug: Glycerin formulation
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin formulation of ototopical 0.3% ciprofloxacin
Study: 9012900
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at a low dose of 10 ppm
Study: 3580158
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (preoperative irradiation followed by radical excision or irradiation alone).
Study: 27391833
Drug: Fat grafting
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat grafting (mean volume of 4.8 cc per foot)
Study: 16632233
Drug: 3x daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3x daily insulin lispro
Study: 16632233
Drug: 3x daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3x daily lispro mid mixture (MidMix; 50% lispro, 50% protaminated lispro)
Study: 16632233
Drug: 1x daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1x daily insulin glargine
Study: 16632233
Drug: 3x daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3x daily lispro mid mixture (MidMix)
Study: 30789801
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Study: 23591657
Drug: Nonopioid medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid medications
Study: 27338193
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus paclitaxel doublet chemotherapy
Study: 27338193
Drug: Monotherapy (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (vinorelbine or gemcitabine)
Study: 22716999
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram daily for 7 days
Study: 12324294
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg/d for infants, 40 mg/d for older children)
Study: 2590267
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg theophylline administered at 8 a.m.
Study: 2590267
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg theophylline administered at 8 p.m.
Study: 2590267
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg theophylline administered at 8 a.m. and 8 p.m.
Study: 21816079
Drug: Non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment group
Study: 29096689
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered indomethacin
Study: 19010927
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen (5 mg/daily)
Study: 26510183
Drug: Patient-Controlled Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Intravenous Analgesia (PCIA)
Study: 23948997
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily S‐1 administration (80‐120 mg/day depending on BSA; days 1‐28 every 6 weeks for 1 year)
Study: 23948997
Drug: Alternate-day S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day S‐1 administration (80‐120 mg/day depending on BSA; alternate days for 15 months)
Study: 19568216
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) training
Study: 31483689
Drug: Somatic yoga
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic yoga and meditation (weekly for 8 weeks, with home program)
Study: 25064681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and psychosocial intervention
Study: 22892337
Drug: Mesalamine 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 2.4 g
Study: 17617807
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine ROUVAX
Study: 12848629
Drug: 15-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-month treatment
Study: 23954387
Drug: Oxiplex/AP gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiplex/AP gel (Intercoat)
Study: 20416952
Drug: Modified Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Early Treatment of Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT)
Study: 18625518
Drug: Cervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical injection
Study: 18625518
Drug: Hysteroscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic injection
Study: 16143698
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, then 75 mg once daily)
Study: 11845882
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for heart failure
Study: 11845882
Drug: Propranolol (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (additional treatment)